{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:05:16Z","timestamp":1782911116032,"version":"3.54.5"},"reference-count":94,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005601","name":"CLL Global Research Foundation","doi-asserted-by":"publisher","award":["00011311"],"award-info":[{"award-number":["00011311"]}],"id":[{"id":"10.13039\/100005601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bneo.2024.100034","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T06:08:34Z","timestamp":1722492514000},"page":"100034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6985-3509","authenticated-orcid":false,"given":"Natalia","family":"Timofeeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0114-8384","authenticated-orcid":false,"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3172-9166","authenticated-orcid":false,"given":"Varsha","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"29","key":"10.1016\/j.bneo.2024.100034_bib1","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.bneo.2024.100034_bib2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O'Brien","year":"2014","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.bneo.2024.100034_bib3","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.bneo.2024.100034_bib4","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O'Brien","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2024.100034_bib5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100034_bib6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.bneo.2024.100034_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.bneo.2024.100034_bib8","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.bneo.2024.100034_bib9","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2024.100034_bib10","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/blood.2019003570","article-title":"Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors","volume":"135","author":"Strati","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2024.100034_bib11","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"33","key":"10.1016\/j.bneo.2024.100034_bib12","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016915","article-title":"Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized trials","volume":"98","author":"Zhou","year":"2019","journal-title":"Medicine (Baltim)"},{"issue":"2","key":"10.1016\/j.bneo.2024.100034_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PLoS One"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100034_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2020-137062","article-title":"Adverse events in clinical trials of ibrutinib and acalabrutinib for B-cell lymphoproliferative disorders: a systematic review and network meta-analysis","volume":"136","author":"Hilal","year":"2020","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bneo.2024.100034_bib15","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/cncr.34787","article-title":"Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: focus on hypertension and cardiovascular toxicity","volume":"129","author":"Gordon","year":"2023","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.bneo.2024.100034_bib16","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.bneo.2024.100034_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, \u03b32 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2024.100034_bib18","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat Commun 7"},{"issue":"13","key":"10.1016\/j.bneo.2024.100034_bib19","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.bneo.2024.100034_bib20","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.bneo.2024.100034_bib21","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jacc.2019.07.057","article-title":"Real-life insight into ibrutinib cardiovascular events: defining the loose ends","volume":"74","author":"Bergler-Klein","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.bneo.2024.100034_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.995522","article-title":"Data mining and safety analysis of BTK inhibitors: a pharmacovigilance investigation based on the FAERS database","volume":"13","author":"Wan","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.bneo.2024.100034_bib23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/17474086.2022.2067526","article-title":"Cardiotoxicity of BTK inhibitors: ibrutinib and beyond","volume":"15","author":"Christensen","year":"2022","journal-title":"Expert Review of Hematology"},{"issue":"5","key":"10.1016\/j.bneo.2024.100034_bib24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: cardiooncology state-of-the-art review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"4","key":"10.1016\/j.bneo.2024.100034_bib25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.bneo.2024.100034_bib26","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100034_bib27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100034_bib28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/hematology.2020000120","article-title":"Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia","volume":"2020","author":"Fischer","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"17","key":"10.1016\/j.bneo.2024.100034_bib29","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.2019002841","article-title":"How I manage CLL with venetoclax-based treatments","volume":"135","author":"Wierda","year":"2020","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bneo.2024.100034_bib30","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","article-title":"Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy","volume":"131","author":"Coutre","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2024.100034_bib31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study","volume":"37","author":"Kater","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100034_bib32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood-2019-123930","article-title":"Four-year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL)","volume":"134","author":"Seymour","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2024.100034_bib33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/bloodadvances.2019000864","article-title":"Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24\u00a0months","volume":"4","author":"Lew","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.bneo.2024.100034_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.hoc.2013.01.002","article-title":"Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications","volume":"27","author":"Herishanu","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"16","key":"10.1016\/j.bneo.2024.100034_bib35","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2024.100034_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.592205","article-title":"Proliferative signals in chronic lymphocytic leukemia; what are we missing?","volume":"10","author":"Haselager","year":"2020","journal-title":"Front Oncol"},{"issue":"25","key":"10.1016\/j.bneo.2024.100034_bib37","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2024.100034_bib38","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/s41418-020-00692-w","article-title":"Regulation of Bcl-XL by non-canonical NF-\u03baB in the context of CD40-induced drug resistance in CLL","volume":"28","author":"Haselager","year":"2021","journal-title":"Cell Death Differ"},{"issue":"17","key":"10.1016\/j.bneo.2024.100034_bib39","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1182\/blood-2012-11-467670","article-title":"IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells","volume":"122","author":"Pascutti","year":"2013","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.bneo.2024.100034_bib40","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1038\/onc.2010.248","article-title":"Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40\/TLR9 triggering","volume":"29","author":"Tromp","year":"2010","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.bneo.2024.100034_bib41","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1182\/blood-2006-05-021683","article-title":"Differential Noxa\/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity","volume":"109","author":"Smit","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2024.100034_bib42","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s41375-023-01898-w","article-title":"Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation","volume":"37","author":"Kielbassa","year":"2023","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bneo.2024.100034_bib43","first-page":"e302","article-title":"Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors","volume":"100","author":"Thijssen","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bneo.2024.100034_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/cdd.2017.159","article-title":"BCL2 and miR-15\/16: from gene discovery to treatment","volume":"25","author":"Pekarsky","year":"2018","journal-title":"Cell Death Differ"},{"issue":"4","key":"10.1016\/j.bneo.2024.100034_bib45","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/leu.2015.316","article-title":"BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia","volume":"30","author":"Chen","year":"2016","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.bneo.2024.100034_bib46","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1182\/bloodadvances.2020003944","article-title":"Extrinsic interactions in the microenvironment in\u00a0vivo activate an antiapoptotic multidrug-resistant phenotype in CLL","volume":"5","author":"Jayappa","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.bneo.2024.100034_bib47","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.bneo.2024.100034_bib48","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.bneo.2024.100034_bib49","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1074\/jbc.RA119.011946","article-title":"Noncatalytic Bruton's tyrosine kinase activates PLC\u03b3(2) variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells","volume":"295","author":"Wist","year":"2020","journal-title":"J\u00a0Biol Chem"},{"issue":"8","key":"10.1016\/j.bneo.2024.100034_bib50","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/bloodadvances.2024012706","article-title":"In BTK, phosphorylated Y223 in the SH3 domain mirrors catalytic activity, but does not influence biological function","volume":"8","author":"Estupi\u00f1\u00e1n","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.bneo.2024.100034_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102555","article-title":"BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma","volume":"298","author":"Yuan","year":"2022","journal-title":"J\u00a0Biol Chem"},{"issue":"11","key":"10.1016\/j.bneo.2024.100034_bib52","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.4049\/jimmunol.171.11.5988","article-title":"Function of Bruton\u2019s tyrosine kinase during B cell development is partially independent of its catalytic activity 1","volume":"171","author":"Middendorp","year":"2003","journal-title":"J\u00a0Immunol"},{"issue":"20","key":"10.1016\/j.bneo.2024.100034_bib53","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance","volume":"6","author":"Blombery","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.bneo.2024.100034_bib54","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase Inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"736","key":"10.1016\/j.bneo.2024.100034_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abg5216","article-title":"Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK","volume":"15","author":"Dhami","year":"2022","journal-title":"Sci Signal"},{"issue":"6682","key":"10.1016\/j.bneo.2024.100034_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.bneo.2024.100034_bib57","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/leu.2016.129","article-title":"Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes","volume":"30","author":"Cervantes-Gomez","year":"2016","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.bneo.2024.100034_bib58","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1182\/bloodadvances.2021004861","article-title":"Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia","volume":"5","author":"Kater","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.bneo.2024.100034_bib59","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41408-021-00429-z","article-title":"Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication","volume":"11","author":"Lu","year":"2021","journal-title":"Blood Cancer J"},{"issue":"22","key":"10.1016\/j.bneo.2024.100034_bib60","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.bneo.2024.100034_bib61","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100034_bib62","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2023-189711","article-title":"Combined ibrutinib and venetoclax for first-line treatment of patients with chronic lymphocytic leukemia (CLL): 5-year follow-up data","volume":"142","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"suppl_1","key":"10.1016\/j.bneo.2024.100034_bib63","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood-2019-131732","article-title":"Combined ibrutinib and venetoclax in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) [abstract]","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"issue":"suppl_1","key":"10.1016\/j.bneo.2024.100034_bib64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2019-121424","article-title":"Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): results from the MRD cohort of the phase 2 CAPTIVATE study [abstract]","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.bneo.2024.100034_bib65","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.bneo.2024.100034_bib66","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"suppl 16","key":"10.1016\/j.bneo.2024.100034_bib67","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1200\/JCO.2023.41.16_suppl.7535","article-title":"Fixed-duration ibrutinib\u00a0+ venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study","volume":"41","author":"Barr","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bneo.2024.100034_bib68","article-title":"Ghia P Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): up to 5 years of follow-up from the FD cohort of the phase 2 CAPTIVATE study","year":"2023","journal-title":"Oral presentation at ASH Annual Meeting"},{"issue":"30","key":"10.1016\/j.bneo.2024.100034_bib69","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100034_bib70","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/blood-2022-166700","article-title":"MRD4 eradication at 6\u00a0months and early clearance of MRD with combination of ibrutinib plus venetoclax results in sustained clinical and MRD responses: exploratory analysis of the blood cancer UK TAP clarity study","volume":"140","author":"Munir","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100034_bib71","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-136960","article-title":"Continued long term responses to ibrutinib + venetoclax treatment for relapsed\/refractory CLL in the blood cancer UK TAP clarity trial","volume":"136","author":"Hillmen","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2024.100034_bib72","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Hillmen","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bneo.2024.100034_bib73","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"S3","key":"10.1016\/j.bneo.2024.100034_bib74","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/01.HS9.0000843472.57904.29","article-title":"The combination of ibrutinib plus venetoclax results in a high rate of MRD negativity in previously untreated CLL: the results of the planned interim analysis of the phase III NCRI FLAIR trial","volume":"S145;6","author":"Hillmen","year":"2022","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100034_bib75","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood-2023-178298","article-title":"Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: report of the phase III UK NCRI FLAIR study","volume":"142","author":"Hillmen","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2024.100034_bib76","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2024.100034_bib77","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evidence"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100034_bib78","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood-2023-187128","volume":"142","author":"Ghia","year":"2023","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bneo.2024.100034_bib79","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1158\/1078-0432.CCR-23-0807","article-title":"A\u00a0CAPTIVATEing analysis for higher-risk CLL","volume":"29","author":"Rogers","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.bneo.2024.100034_bib80","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood-2018-06-860593","article-title":"A\u00a0pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia","volume":"132","author":"Chen","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2024.100034_bib81","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-020-00870-w","article-title":"Ibrutinib dose modifications in the management of CLL","volume":"13","author":"Hardy-Abeloos","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"18","key":"10.1016\/j.bneo.2024.100034_bib82","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1182\/bloodadvances.2023010236","article-title":"Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study","volume":"7","author":"Moreno","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.bneo.2024.100034_bib83","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/jha2.427","article-title":"A\u00a0review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies","volume":"3","author":"Sharman","year":"2022","journal-title":"eJHaem"},{"issue":"20","key":"10.1016\/j.bneo.2024.100034_bib84","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1158\/1078-0432.CCR-22-0504","article-title":"Effective tumor debulking with ibrutinib before initiation of venetoclax: results from the CAPTIVATE minimal residual disease and fixed-duration cohorts","volume":"28","author":"Barr","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.bneo.2024.100034_bib85","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.CCR-22-3934","article-title":"Absence of BTK, BCL2, and PLCG2 mutations in chronic lymphocytic leukemia relapsing after first-line treatment with fixed-duration ibrutinib plus venetoclax","volume":"30","author":"Jain","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.bneo.2024.100034_bib86","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1158\/1078-0432.CCR-23-2872","article-title":"Overcoming resistance in chronic lymphocytic leukemia\u2014maybe less is more?","volume":"30","author":"Al-Sawaf","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100034_bib87","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood-2023-179541","volume":"142","author":"Tam","year":"2023","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.bneo.2024.100034_bib88","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood.2023019706","article-title":"Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy","volume":"143","author":"Liu","year":"2024","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.bneo.2024.100034_bib89","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1158\/1078-0432.CCR-21-4037","article-title":"Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy","volume":"28","author":"Deng","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bneo.2024.100034_bib90","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13045-021-01188-x","article-title":"Concurrent ibrutinib plus venetoclax in relapsed\/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study","volume":"14","author":"Wang","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.bneo.2024.100034_bib91","article-title":"Ibrutinib Combined with Venetoclax in Patients with Relapsed\/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study","author":"Wang","year":"2023","journal-title":"Oral presentation at ASH Annual Meeting"},{"issue":"7","key":"10.1016\/j.bneo.2024.100034_bib92","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood.2023022420","article-title":"Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-na\u00efve Waldenstr\u00f6m macroglobulinemia","volume":"143","author":"Castillo","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2024.100034_bib93","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00277-021-04535-7","article-title":"Ibrutinib combined with venetoclax for the treatment of relapsed\/refractory diffuse large B cell lymphoma [abstract]","volume":"100","author":"Zhou","year":"2021","journal-title":"Ann Hematol"},{"issue":"21","key":"10.1016\/j.bneo.2024.100034_bib94","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.2023020158","article-title":"Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up","volume":"142","author":"Thompson","year":"2023","journal-title":"Blood"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:37:20Z","timestamp":1778938640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2950328024000347"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100034","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100034"}}